(BGM) Qilian International - Ratings and Ratios

BGM Group Ltd, formerly known as Qilian International Holding Group Limited, is a China-based pharmaceutical and agrochemical company listed on the NASDAQ under the ticker symbol BGM. Since its incorporation in 2019, the company has specialized in manufacturing and distributing active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and related by-products. Its product portfolio includes licorice derivatives, such as Gan Di Xin, used as an antitussive and expectorant, and Qilian Shan Licorice Extract, which serves as a key ingredient for pharmaceutical companies producing traditional licorice tablets. The company also offers Qilian Shan licorice liquid extract, a primary component for manufacturing compound licorice oral solutions.

BGM Group Ltd provides veterinary and human healthcare solutions through its Qilian Shan oxytetracycline tablets and APIs, which are used to prevent and treat diseases in livestock and humans. Additionally, the company produces TCMD products, including Ahan antibacterial paste for treating chronic skin conditions and heparin sodium preparations for cardiovascular and cerebrovascular medications. Its non-pharmaceutical offerings include Zhu Xiaochang sausage casings for culinary applications and Xiongguan organic and organic-inorganic compound fertilizers, designed to enhance crop yields and soil health. The company operates from its headquarters in Chengdu, Sichuan Province, China, and maintains a strong focus on research, development, and distribution across its diversified product lines.

Based on the provided and , BGM Group Ltd is currently trading at $10.59 with a 20-day average volume of 9,214 shares. Its short-term moving averages (SMA 20: $10.07, SMA 50: $9.91) suggest a recent uptrend, while the long-term SMA 200 ($7.16) indicates significant growth over the past year. The Average True Range (ATR) of 1.13 reflects moderate volatility. From a fundamental perspective, the company has a market capitalization of $46.83 million, with a price-to-book (P/B) ratio of 1.08 and a price-to-sales (P/S) ratio of 1.57. However, the negative return on equity (RoE) of -3.38% signals potential profitability challenges.